A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
Timothy Hagerty
Advertisement
Timothy Hagerty is scientist at Pfizer Global Research and Development Global Biologics, Bioprocess R&D
Articles by Timothy Hagerty
A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
Advertisement
Latest Updated Articles
The Development and Application of a Monoclonal Antibody Purification PlatformPublished: October 2nd 2009 | Updated:
The Development and Application of a Monoclonal Antibody Purification PlatformPublished: March 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Regulatory Challenges for Global Manufacturing of Vaccines
2
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
3
Welcome to CPHI Frankfurt 2025
4
Q&A: An Evolution in Enzyme Engineering with Zymvol’s Marina Cañellas
5
